Table 6.
Summary of live virus microneutralizing titre (MN titre).
| High-Dose (n = 12) | Low-Dose (n = 11) | Placebo (n = 6) | |
|---|---|---|---|
| Day 0 (pre-dose) | 5 (5–5) | 5 (5–5) | 5 (5–5) |
| Day 7 | 5 (5–5) | 5 (5–5) | 5 (5–5) |
| Day 14 | 5 (5–5) | 5 (5–5) | 5 (5–5) |
| Day 28 (pre-dose) | 5 (5–5) | 5 (5–5) | 5 (5–5) |
| Day 35 | 5 (5–5) | 5 (5–5) | 5 (5–5) |
| Day 42 | 5 (5–5) | 5 (5–5) | 5 (5–5) |
| Day 56 | 5 (5–5) | 5 (5–5) | 5 (5–5) |
Date are geometric mean titre (95% confidence interval). High-dose: DelNS1-nCoV-RBD LAIV (1 × 107.7 EID50/dose) in 0.2 mL. Low-dose: DelNS1-nCoV-RBD LAIV (1 × 107 EID50/dose) in 0.2 mL. Placebo: inert excipients/ dose in 0.2 mL. MN titre ≥ 10 was considered as positive.